No Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal
Delaware's Chancery Court sent toward trial Thursday two counts of a class suit alleging costly disclosure failures and Tammany Hall-flavored scheming by directors and officers of biotech venture Bioverativ Inc. to...To view the full article, register now.
Already a subscriber? Click here to view full article